IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bosco who wrote (200)	10/7/1997 4:06:00 PM
From: David Bleich	of 305

To all interested: I spoke with Cheryl Borque today, Immulogics new director of investor relations. Nothing major to report, but IMUL has submitted safety data to the FDA regarding its previous Ragweed trial. They will continue to submit data and work with the FDA to make sure that the Ragweed trial goes forward next summer. Secondly, the Cocaine program is going forward. IMUL expects to submit an IND for the human phase I trial in Oct/Nov 1997. This is good news. This study is funded by a 2.2 million dollar federal grant. Third, they are in the early stages of a nictoine vaccine. Finally, no apparent corporate sponsorship will happen until the ragweed data is available next year. Also the is no intention of floating more shares and the burn rate should be down considerably from ~6 million per quarter. Marr is working very hard to regain FDA support and confidence. I think the future looks bright for this company if they can turn the corner next summer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next